Matinas BioPharma Reports 2023 Financial Results and Provide

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...

Related Keywords

Bedminster , Pennsylvania , United States , Philadelphia , San Diego , California , New Jersey , Michigan , American , America , Jeromed Jabbour , Matinas Biopharma , Jody Cain , Asia Pacific , Johns Hopkins , World Health Organization , Data Review Committee , Vanderbilt University Medical Center , University Of California , University Of Michigan , Memorial Sloan Kettering Cancer Center , Compassionate Expanded Use Access Program , Oncology Program , National Institutes Of Health , Matinas Biopharma Holdings Inc , Small Oligonucleotide Inflammation Program , Genentech Inc , Oral Amphotericinb Program , American Company , Corporate Development , San Diego School Of Medicine , Key Program Updates , Expanded Use Access Program , Biopharma Holdings , Chief Executive Officer , Fungal Priority Pathogen List , Critical Priority , South America , Middle East , Data Safety Monitoring Board , Expanded Use Access , Nationwide Children , National Institutes , San Diego School , Oligonucleotide Inflammation Program , Private Securities Litigation Reform Act , Year Ended December , Markets ,